Mar 25, 2015 at 19:18 | Source: CNBC-TV18
With Sun Pharma-Ranbaxy merger complete, Sun is now India's largest and the world's fifth largest drug maker with combined revenue of USD 5.14 billion
Mar 10, 2015 at 12:00 | Source: Moneycontrol.com
BF Utilities rallied 8 percent in addition to 14 percent upside in previous session while SPARC climbed over a percent after rising 15 percent on Monday.
Mar 09, 2015 at 12:41 | Source: CNBC-TV18
Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. We have JSPL, Himatsingka Seide, CONCOR, MindTree, SPARC, Nitesh Estates and Shilpi Cable.
Mar 05, 2015 at 18:21 | Source: PTI
In two trading sessions, the company has now jumped 15 percent. Shares of the company on Thursday surged ten percent to touch its 52-week high and upper circuit level of Rs 473.55.
Mar 05, 2015 at 14:00 | Source: Moneycontrol.com
Sun Pharma, HUL, HDFC twins and Cipla were top gainers in the Sensex. Hindalco, Coal India, GAIL, TCS and Sesa Sterlite are major laggards.
Mar 04, 2015 at 15:10 | Source: Moneycontrol.com
Shares of Sun Pharmaceutical Industries and Sun Pharma Advanced Research Company (SPARC) rallied 9-10 percent intraday on Wednesday to hit record highs of Rs 1,035 and Rs 448.80, respectively. SPARC, the subsidiary of pharma major, has received approval from US Food and Drug Administration (USFDA) for antiepileptic drug.
Mar 04, 2015 at 13:10 | Source: CNBC-TV18
Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. We have- Sparc, Sun Pharma, Essar Ports, Nitesh Estates & NBCC.
Mar 04, 2015 at 12:00 | Source: Moneycontrol.com
Sun Pharma topped the buying list on Sensex, up 6 percent. Even its subsidiary Sun Pharma Advanced Research Company gained 6 percent on getting US FDA nod for Elepsia XR extended release tablets, an anti-epileptic drug. SPARC says product will be manufactured by Sun Pharma at Halol unit.
Mar 04, 2015 at 10:13 | Source: Moneycontrol.com
Sun Pharma Advanced Research Company today announced that the USFDA has approved its New Drug Application (NDA) for ELEPSIA XRTM (Levetiracetam extended-release tablets 1000 mg and 1500 mg). ELEPSIA XRTM is indicated for adjunctive therapy in the treatment of partial onset seizures in patients 12 years of age and older with epilepsy.
Feb 13, 2015 at 11:36 | Source: Moneycontrol.com
Sparc Systems has reported a standalone total income from operations of Rs 0.03 crore and a net loss of Rs 0.07 crore for the quarter ended Dec '14